Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation

Objective During the first wave of the SARS-CoV-2 pandemic, management of anticoagulation therapy in hospitalized patients with atrial fibrillation (AF) was simplified to low-molecular-weight heparin (LMWH) followed by oral anticoagulation, mainly owing to the risk of drug–drug interactions. However...

Full description

Bibliographic Details
Main Authors: Pável Olivera, César Velásquez-Escandón, Desirée Campoy, Katia Flores, Tania Canals, Erik Johansson, María José Herranz, Laia Martínez, Juan José Cerezo-Manchado, Ramón Salinas
Format: Article
Language:English
Published: SAGE Publishing 2023-06-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296231180865

Similar Items

Similar Items